https://www.thebodypro.com/category/meeting-costs-hiv-care/tag/conference-coverage

The Latest

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014 Img

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014

An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug Img

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug

HCV drugs are priced out of reach and out of control.

-- Michel Sidibé, UNAIDS

MELBOURNE, Australia -- Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead...

CROI 2014: Fair Pricing Coalition Seeks to Increase Access to HIV and HCV Treatment (Video) Img

CROI 2014: Fair Pricing Coalition Seeks to Increase Access to HIV and HCV Treatment (Video)

Lynda Dee of the Fair Pricing Coalition (FPC) spoke with coworkers Jeff Berry and Murray Penner, as well as David Evans of Project Inform, about access to HIV and hepatitis C (HCV) medications. FPC negotiates with pharmaceutical companies to make the...

Promo Image

High Prices for Antiretrovirals in Middle-Income Countries Outside Africa

Middle-income countries outside of Africa are paying, on average, four times more for antiretrovirals than African countries with similar Gross National Incomes (GNI) according to an analysis presented at IAS 2013.

There have been substantial reduct...

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It? Img

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

A single drug dose, taken no more than once a month, to treat HIV: It's no longer the stuff of idle fantasy. But in a world stuffed with excellent once-a-day drugs, will long-acting meds have value?

Non-African Middle-Income Countries Pay Four Times More for ARVs Than African Middle-Income Countries Img

Non-African Middle-Income Countries Pay Four Times More for ARVs Than African Middle-Income Countries

Compared to wealthy nations and poor nations, "middle-class" countries are getting squeezed out of the HIV treatment market, a new study asserts.

The Social and Economic Determinants of HIV/AIDS: Time for Action Img

The Social and Economic Determinants of HIV/AIDS: Time for Action

As she moved from presentation to presentation at the XIX International AIDS Conference earlier this year, global health consultant Alexis Martin writes that she "was disappointed to find that discussion focused more on describing the problem than id...

Promo Image

AIDS 2012 News Media Roundup

A roundup of news from the International AIDS Conference taking place this week in Washington.

Treating Everybody With HIV Is the Goal, But Who Will Pay? The big question hanging over the International AIDS Conference this week is whether all 34 mil...

Promo Image

Building Local Networks That Can Respond to National, State and Local Challenges: A Blog Entry From Positive Policy

I am freaked by the 1840 folks on ADAP waiting lists (as of June 24th)*. I just never thought this would happen in America. I can't imagine the fear and anger you must feel when you have to piece together your medications through various patient ass...